Asahi Kasei Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Asahi Kasei Corporation
Boryung’s chief technology officer outlines R&D strategy to move forward as a Korea-based global pharma firm and how domestic pharmas are juggling new drug development and generating cash cows.
The Danish diabetes titan teams with Moderna’s founder on cardiometabolic R&D. Troubled cell therapy biotech Bone Therapeutics negotiates reverse merger with Medsenic.
Emerging Company Profile: The British biotech, co-founded by experimental researcher Lady Amanda Feilding, is developing psychedelics therapeutics for a rare but debilitating headache disorder and mental health disorders.
Public Company Edition: Only nine drug developers went public in the US, raising $807m in the first quarter, versus 32 IPOs raising $5.2bn in Q1 of last year. Also, MoonLake closed its SPAC merger, Sanofi priced €650m in sustainability-linked bonds in €1.5bn note sale, and Kaleido will cease operations.
- Medical Devices
- Other Names / Subsidiaries
- Advanced Circulatory Systems, Inc.
- Artisan Pharmaceuticals
- Asahi Kasei Holdings US, Inc.
- Asahi Kasei Pharma America Corp. (AKP America)
- Cardiac Science Corporation
- Golden Hour Data Systems, Inc.
- Kyma Medical Technologies, Ltd.
- Mobilize RRS LLC.
- TherOx, Inc.
- Veloxis Pharmaceuticals Inc.
- ZOLL Medical Corporation